-- 加拿大皇家银行资本市场（RBC Capital Markets）周二发布的一份报告指出，Insmed（INSM）的Brinsupri疗法获得了医生们的积极反馈。医生们对该药物的特性表示满意，并预计其在短期和长期内使用量将会增加。 Brinsupri是由Insmed公司研发的一种处方药，用于治疗非囊性纤维化支气管扩张症。 报告显示，一项针对50位医生的调查显示，受访者对该药物持积极态度，并表示潜在的适用患者群体可能会随着时间的推移而扩大。 RBC表示，调查表明，支气管扩张症市场主要由中等和高处方量的医生主导，这可能有助于该药物的早期上市。 此外，该公司指出，支付方的动态似乎可控，大多数受访医生认为拒付并非主要障碍。 RBC预计，Brinsupri在2026年的销售额将达到约13.5亿美元，其中包括第一季度约2.013亿美元的销售额。 RBC维持对Insmed的“跑赢大盘”评级，并将目标价从212美元上调至216美元。
Price: $152.47, Change: $+1.33, Percent Change: +0.88%
Shanxi Lu'an Environmental Energy Development (SHA:601699) posted 2025 attributable net profit of 1.12 billion yuan, down 54% from 2.45 billion yuan the previous year.Earnings per share declined to 0.37 yuan from 0.82 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue fell 22% year over year to 27.8 billion yuan from 35.9 billion yuan.Shares of the coal miner rose 3% in recent trade.
WA1 Resources (ASX:WA1) reported a cash balance of about AU$131 million as at March 31, according to a Monday Australian bourse filing.The company said it has now received all data inputs for a mineral resource estimate update expected in the June quarter.The company completed essential data capture activities in 2025, which is now facilitating project development studies, permitting and approvals workstreams, the filing added.The company's shares rose 7% in recent Monday trade.
Bank of Ningbo (SHE:002142) posted first-quarter attributable net profit of 8.18 billion yuan, up 10% from 7.42 million yuan the previous year.Earnings per share rose to 1.24 yuan from 1.12 yuan, according to a weekend filing with the Shenzhen bourse.Operating income rose 10% year over year to 20.4 billion yuan from 18.5 billion yuan.Shares of the bank rose 3% in recent trade.